CD274 and neoplasm: In the phase 3 Checkmate186 trial, a considerably higher benefit was observed in patients treated with nivolumab and chemotherapy in tumors with ≥1% PD-L1 expression in tumor cells compared with tumors with <1% expression of PD-L1 [12].